Form 4: Maze Therapeutics Director Reports Stock Gift

Maze Therapeutics Director Charles J. Homcy reported a gift of 7,422 shares of common stock on May 4, 2026.

Summary

• Charles J. Homcy, a Director at Maze Therapeutics, Inc., reported a transaction on May 4, 2026.
• The transaction involved a gift of 7,422 shares of common stock, with no consideration exchanged.
• This gift is exempt from reporting requirements under Rule 16b-5.
• Following this transaction, Mr. Homcy beneficially owns 31,113 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider stock gift transaction exempt from standard reporting rules and provides no new financial or operational information.

Positives

• Director Charles J. Homcy continues to hold a significant stake in Maze Therapeutics, with 31,113 shares beneficially owned.
• The transaction was a gift, indicating no sale or divestment of shares by a key insider.

Negatives

• No financial performance or operational updates are provided in this filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide strategic or financial performance insights. This filing indicates a non-sale event by a director.

Stakeholder Impact

• Shareholders: The gift of stock by a director does not directly impact share price or company fundamentals but confirms continued insider interest.

Key Dates

Keywords

Maze Therapeutics, SEC Form 4, Insider Trading, Stock Gift, Beneficial Ownership, Director Transaction, Rule 16b-5